Related Experiment Video
Updated: Jul 20, 2026

A Simplified Model for Heterotopic Heart Valve Transplantation in Rodents
Published on: September 21, 2021
Simultaneous heart and kidney transplantation for combined cardiac and renal failure
1Department of Surgery, National Taiwan University Hospital, No. 7 Chung-shan South Road, Taipei, Taiwan. sswang@ha.mc.ntu.edu.tw
Insights
Simultaneous heart and kidney transplantation (SHKT) is a viable option for patients with combined heart and kidney failure. This review of a 10-year experience shows good short- and long-term survival rates for SHKT.
Area of Science:
- Nephrology
- Cardiology
- Transplantation Immunology
Background:
- Combined end-stage heart and kidney failure presents complex therapeutic challenges.
- Simultaneous heart and kidney transplantation (SHKT) offers a potential solution for select patients.
Purpose of the Study:
- To review the 10-year experience with simultaneous heart and kidney transplantation.
- To evaluate the feasibility, outcomes, and survival rates of SHKT.
Main Methods:
- Retrospective review of six patients who underwent SHKT between June 1995 and December 2004.
- Analysis of patient demographics, indications for transplantation, immunosuppressive protocols, and survival data.
Main Results:
- No operative mortality was observed.
- One-year and five-year survival rates were 83%, with a 10-year survival rate of 55%.
- No instances of cardiac or renal allograft rejection or renal allograft loss were reported.
Conclusions:
- Simultaneous heart and kidney transplantation is a feasible procedure with good short- and long-term outcomes.
- SHKT can be successfully performed without increasing immunosuppressive therapy requirements.
- End-stage failure of either the heart or kidney does not preclude combined transplantation.
Abstract:
Simultaneous heart and kidney transplantation (SHKT) is feasible for combined cardiac and renal failure. Herein we reviewed our 10-year experience in SHKT. Six patients underwent SHKT from June 1995 to December 2004. Their ages ranged from 13 to 63 years old with a mean of 45.5 +/- 15.8 years. They were all men except one girl, who was the youngest (aged 13) who suffered from dilated cardiomyopathy with congestive heart failure and chronic renal failure due to systemic lupus erythematosus. Because of aggravating heart failure, she changed from hemodialysis to peritoneal dialysis. Because of intractable heart failure, she underwent SHKT from a 24-year-old female donor. All received hemodialysis before SHKT. The indications for heart transplantation included dilated cardiomyopathy (n = 3), ischemic cardiomyopathy (n = 1), cardiac allograft vasculopathy (n = 1), and cardiac allograft failure (n = 1). The immunosuppressive protocol and rejection surveillance were these employed for heart transplantation. No operative mortality was noted in this study. The 1-year and 5-year survival rates were the same, 83%. The 10-year survival rate was 55%. No cardiac or renal allograft rejection was noted. No renal allograft loss was noted. There were two late mortalities: the one, who underwent redo heart transplantation for coronary artery vasculopathy died of cardiac allograft failure 1 year after SHKT. The other patient died of massive ischemic necrosis of the intestine at 6 years after SHKT. Our experience showed that SHKT had good short- and long-term results without increasing immunosuppressive doses. End-stage failure of either the heart or the kidney did not preclude heart plus kidney transplantation.
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure

